| 童 宁,唐玉璋,马 力,沈 洁,高湘旻,张建峰.奥拉西坦联合阿托伐他汀对血管性认知障碍患者血清NO、MMP-9、ET-1水平的影响[J].,2021,(9):1678-1681 |
| 奥拉西坦联合阿托伐他汀对血管性认知障碍患者血清NO、MMP-9、ET-1水平的影响 |
| Effect of Oxiracetam Combined with Atorvastatin on Serum NO, MMP-9 and ET-1 in Patients with Vascular Cognitive Impairment |
| 投稿时间：2020-11-05 修订日期：2020-11-27 |
| DOI：10.13241/j.cnki.pmb.2021.09.017 |
| 中文关键词: 奥拉西坦 阿托伐他汀 血管性认知障碍 一氧化氮 基质金属蛋白酶-9 内皮素-1 |
| 英文关键词: Oxiracetam Atorvastatin Vascular cognitive impairment Nitric oxide Matrix metalloproteinase-9 Endothelin-1 |
| 基金项目:国家卫生计生委医药卫生科技发展项目（W2015CAE173） |
|
| 摘要点击次数: 974 |
| 全文下载次数: 748 |
| 中文摘要: |
| 摘要 目的：研究奥拉西坦联合阿托伐他汀对血管性认知障碍患者血清血清一氧化氮 (Nitric oxide, NO)、基质金属蛋白酶(Matrix metalloproteinases, MMP)-9和内皮素(Endothelin, ET)-1水平的影响。方法：选择2015年1月～2019年12月于我院诊治的70例血管性认知障碍患者，随机分为两组。对照组单独服用奥拉西坦，每天3次，每次0.8 g；观察组联合服用阿托伐他汀，每天晚上1次，每次20 mg。比较两组的简易精神智能量表（MMSE）和蒙特利尔认知评估量表（MoCA）评分，血清NO、MMP-9、ET-1水平、纤维蛋白原、总胆固醇、血浆黏度、甘油三酯水平。结果：治疗后，观察组的有效率明显高于对照组(P<0.05)；两组的MMSE评分和Mo CA评分、血清NO水平明显升高，血清MMP-9和ET-1水平、纤维蛋白原、总胆固醇、血浆黏度、甘油三酯水平显著降低(P<0.05)，且观察组的上述指标显著优于对照组(P<0.05)。结论：奥拉西坦联合阿托伐他汀对血管性认知障碍患者有较好的调脂作用，能改善其认知功能和血液流变学，其机制可能与改善血清NO、MMP-9、ET-1水平有关。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effect of oxiracetam combined with atorvastatin on serum nitric oxide (no), matrix metalloproteinases (MMP) - 9 and endothelin (ET) - 1 levels in patients with vascular cognitive impairment. Methods: A total of 70 patients with vascular cognitive impairment, who were treated in the Second Affiliated Hospital of Southeast University from January 2015 to December 2019, were selected and randomly divided into two groups. The control group was given oxiracetam alone, three times a day, 0.8 g each time; the observation group was given oxiracetam combined with atorvastatin, 20 mg each time, once a night. The scores of MMSE and Moca, the levels of serum NO, MMP-9, ET-1, fibrinogen, total cholesterol, plasma viscosity and triglyceride were compared between the two groups. Results: After treatment, the effective rate of the observation group was significantly higher than that of the control group (P<0.05). The MMSE score and Mo CA score, serum NO levels of the two groups were significantly increased, but the serum MMP-9 and ET-1 levels, fibrinogen, total cholesterol, plasma viscosity, and triglyceride levels were significantly reduced (P<0.05), and the above indicators in the observation group were significantly better than those in the control group (P<0.05). Conclusion: Oxiracetam combined with atorvastatin has better effect of regulating lipid on patients with vascular cognitive impairment, and can improve their cognitive function and hemorheology. The mechanism may be related to the improvement of serum NO, MMP-9, ET-1 levels. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
